Novartis Czech Republic - Net Debt/EBITDA

Novartis Czech Republic`s Net Debt/EBITDA reached 0.371 in 2017. This is 251 % more than in the previous year.

$1.99

Buy Net Debt/EBITDA data for Novartis Czech Republic.

$19.99

Buy all data for Novartis Czech Republic.

from $199/month

Buy annual subscriptions for all our products.

 
Company Unit 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Amgen Czech Republic ... ... ... ... ...             0 0 -0.005 0.709 1.53    
Bayer Czech Republic ... ... ...                 -0.298 -0.098 0.140 0.150 0.890    
GlaxoSmithKline Czech Republic ... ... ...                 0.438 1.02 1.69 -0.001 -3.71    
Merck Czech Republic ... ...                   1.87 1.39 2.80 0.353 -0.026    
Novartis Czech Republic                       3.22 0.696 -0.064 0.826 -0.015    
Pfizer Czech Republic ... ...                   2.16 -1.32 -0.141 -1.65 -0.037    
Roche Czech Republic ... ... ...                 -0.002 0.737 0.867 2.04 3.15   ...
Sanofi-Aventis Czech Republic ... ... ... ...               12.8 16.5 8.87 27.7 4.27    
Servier Czech Republic ... ... ... ... ... ... ... ... ... ... ... ... -1.54 -2.09 -1.74 -0.839    
Walmark ... ... ...                 0.471 4.81 4.37 2.26 -5.37